Today we are writing in @Aftenposten about the new #protontherapy centers soon to open @Oslounivsykehus and @haukeland_no. Read to find out why the cyclotron at the Radiumhospital is named «Ellen Gleditsch». @DNVA1 #EirikMalinen #MarianneGuren @UniOslo https://t.co/nBBLy5VCan

#HSØ har tradisjonen tro delt ut de beste førjulsgaver i form av tildelinger til nye forskningsprosjekter. Vi gratulerer @KjetilTasken og @AmundJon med to av disse tildelingene: https://t.co/lRN6LIDhbd

Stort engasjement på Symposium om offentlig tjenesteinnovasjon på @DNVA1 denne uken. Hva kjennetegner offentlig tjenesteinnovasjon? Hvordan sette i gang endringsprosesser? Takk til @KjetilTasken for en fantastisk dag👏 https://t.co/4vdzHkICBo

Vi er glade for å kunne kunngjøre at Novartis er første legemiddelselskap som offisielt er inne i vår nye forsker-initierte studie MATRIX-RARE👏 Les mer om studien og samarbeidet: https://t.co/8PAfyKJ1Oj @HellandAslaug @KjetilTasken @Oslounivsykehus #TarjeBergdahl #Novartis

We congratulate all the 27 cancer researchers that today received funding from the Norwegian Cancer Society 👏 We are excited that two projects connected to MATRIX are funded and congratulate @HellandAslaug, @KjetilTasken and their research teams:

The international lung cancer day, started with a focus from the TV-show "GodMorgenNorge". Despite important improvements for subgroups of patients, lung cancer is still a disease with a poor prognosis, and more research is needed. @Lungekreft

#Johnson&Johnson joins #IMPRESS-Norway @HellandAslaug @KjetilTasken @HRussnes @OusResearch @SveaassAnne @PRIMEROSE_EU @PCM4EU https://t.co/TJMyUMOiZF

Lær mer om pasientsentrert behandling innen kreftbehandling og satsningen MyPath: https://t.co/5xtQu1kME7 @KaasaStein @LundebyTonje

We congratulate @SigridSkanland and the CLL-OUTCOME consortium on receiving funding from #EP PerMed👏: https://t.co/VTUvFkqra7 @OusResearch @Oslo universitetssykehus @KjetilTasken @HellandAslaug @HRussnes

Nytt håp for #Brystkreftpasienter med hjernemetastaser! Studieresultater viser at Enhertu gir sterk effekt hos HER2-positive pasienter. Med godkjenning fra Beslutningsforum kan behandlingen tas i bruk umiddelbart. #Onkologi #Kreftforskning #ESMO2024 https://t.co/vMVxwxNx1d

Thank’s to all the organizers for two fantastic days at the Norwegian Cancer Symposium, marking the 70th aniversary of the ICR! Inspiring talks, good discussions, two vibrant poster sessions with almost 200 posters as well as delicious food👏👏👏

The Norwegian Cancer Symposium 2024 is marking the 70th anniversary of Institute for Cancer Research at @Oslounivsykehus. Keynote speaker #DouglasHanahan kicked-off the scientific program with an excellent talk about Hallmarks of Cancer 2024.

Norwegian Cancer Symposium, Sept 9-10, 2024, celebrating 70 years of #CancerResearch at Institute for Cancer Research, @Oslounivsykehus, starts with >430 participants, speakers & invited guests. Look forward to talks by 15 invited speakers, 8 short talk speakers, and 118 posters.

Er du interessert i presisjonsmedisin og vil bli vår nye forskningskoordinator? Vi søker nå en prosjektkoordinator for to nasjonale kliniske studier: IMPRESS-Norway og MATRIX-RARE. Søknadsfrist 18. august: https://t.co/LgFZVuwTLl

The next Acta Oncologica Nordic Precision Cancer Medicine Symposium will take place in Oslo 15-17 September 2025 - save the date! A special NPCM symposium collection originating from the NPCM2023 conference has now been published. For more information: https://t.co/pL0w51fnVC

Warm congratulations to @KjetilTasken on receiving the Excellent Researcher Award at @Oslounivsykehus 👏👏 https://t.co/KUCabZ5NtK

PCM4EU’s white paper on molecular assays and molecular tumor boards for trial inclusion has been published in Journal of Internal Medicine👏 - many congratulations: https://t.co/OI3qlmQtFX

Are you looking for a PhD position and are interested in precision cancer medicine? Open position in @HellandAslaug’s group at OUH. The position is connected to a new clinical trial MATRIX-RARE:

The PCM4EU Spring Academy Opening Symposium hosted by @IPOPorto is addressing precision cancer medicine, focussing both on the past, the present & the future. Thanks to all the speakers for excellent presentations and discussions!

Looking forward to the PRIME-ROSE project meeting and the Opening Symposium of the PCM4EU Spring Academy April 3. The Opening Symposium is accessible also digitally - check out the attachment for program and link to the streaming: